

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 1 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
ADHD Agents														
Amphetamine mixed salts	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Atomoxetine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Dexamfetamine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Dexmethylphenidate	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Guanfacine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Lisdexamfetamine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Methylphenidate	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Anaesthetics & Muscle Relaxants														
Alcuronium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bupivacaine	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Cisatracurium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclobenzaprime	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Desflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexmedetomidine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Enflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etidocaine	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Halothane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isoflurane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ketamine	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Methocarbamol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propofol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Rocuronium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sevoflurane	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Sufentanil	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Suxamethonium (succinylcholine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tetracaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thiopental	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tizanidine	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Vecuronium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Analgesics														
Alfentanil	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Aspirin	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Buprenorphine	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Butalbital	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Celecoxib	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Codeine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Dextropropoxyphene	▲	◆	◆	▲	◆	●	◆	●	▲	◆	◆	▲	▲	◆
Diamorphine (diacetylmorphine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diclofenac	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Dihydrocodeine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Etoricoxib	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Fentanyl	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Hydrocodone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Hydromorphone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ibuprofen	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Indometacin (Indomethacin)	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Ketoprofen	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Ketorolac	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Mefenamic acid	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Meloxicam	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Metamizole	●	●	◆	●	■	■	■	■	●	■	●	●	●	◆
Methadone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Morphine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nabumetone	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Naproxen	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Nimesulide	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 2 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Analgesics (continued)														
Oxycodone	▲	◆	◆	▲	◆	■	◆	■	▲	◆	◆	▲	▲	◆
Paracetamol (Acetaminophen)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pethidine (Meperidine)	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Piroxicam	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Remifentanyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tapentadol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Tramadol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Antiarrhythmics														
Amiodarone	▲	◆	◆	▲	■	●	■	●	▲	■	◆	▲	▲	◆
Bepiridil	◆	◆	◆	◆	■	●	■	●	◆	■	◆	◆	◆	◆
Digoxin	◆	◆	◆	◆	■	◆	■	◆	◆	■	■	◆	◆	◆
Disopyramide	◆	◆	◆	◆	■	●	■	●	◆	■	◆	◆	◆	◆
Dofetilide	◆	◆	◆	◆	■	●	■	●	◆	■	◆	◆	◆	◆
Dronedarone	◆	◆	▲	◆	■	■	■	■	◆	■	■	◆	◆	◆
Flecainide	◆	◆	◆	◆	■	●	■	■	◆	■	◆	◆	◆	◆
Lidocaine (Lignocaine)	◆	◆	◆	◆	■	●	■	◆	◆	■	◆	◆	◆	◆
Mexiletine	◆	◆	◆	◆	■	■	■	▲	◆	■	◆	◆	◆	◆
Propafenone	◆	◆	◆	◆	■	■	■	▲	◆	■	◆	◆	◆	◆
Quinidine	▲	◆	◆	▲	■	●	■	■	▲	■	◆	▲	▲	◆
Antibacterials														
Amikacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amoxicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ampicillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azithromycin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Bedaquiline	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Capreomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefalexin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefazolin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefepime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefixime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefotaxime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftazidime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ceftriaxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cefuroxime	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chloramphenicol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ciprofloxacin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Clarithromycin	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Clavulanic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clindamycin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Clofazimine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cloxacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cycloserine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dapsone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Delamanid	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Doxycycline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ertapenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erythromycin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Ethambutol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ethionamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flucloxacillin	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Fosfomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fusidic acid (oral or IV)	◆	◆	◆	◆	◆	■	◆	●	◆	◆	●	◆	◆	◆
Fusidic acid (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gentamicin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Imipenem/Cilastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isoniazid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Kanamycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levofloxacin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Linezolid	■	■	◆	■	◆	●	◆	◆	■	◆	■	■	■	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 3 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Antibacterials (continued)														
Meropenem	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metronidazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moxifloxacin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Nitrofurantoin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ofloxacin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Para-aminosalicylic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Penicillins	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piperacillin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyrazinamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rifabutin	◆	◆	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Rifampicin (Rifampin)	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Rifapentine	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Rifaximin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Spectinomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Streptomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfadiazine	◆	◆	◆	◆	◆	▲	◆	■	◆	◆	◆	◆	◆	◆
Tazobactam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telithromycin	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Tetracyclines	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tinidazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trimethoprim/Sulfamethoxazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vancomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anti-coagulant, Anti-platelet and Fibrinolytic														
Acenocoumarol	▲	◆	◆	▲	■	■	■	●	▲	■	◆	▲	▲	◆
Apixaban	▲	◆	◆	▲	■	■	◆	■	▲	■	◆	▲	▲	◆
Argatroban	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆
Aspirin (anti-platelet)	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Betrixaban	◆	◆	◆	◆	■	■	◆	◆	◆	■	◆	◆	◆	◆
Cilostazol	■	■	◆	■	◆	●	◆	■	■	◆	■	■	■	◆
Clopidogrel	▲	◆	◆	▲	◆	●	◆	■	▲	◆	◆	▲	▲	◆
Clopidogrel (recently stented patients)	▲	◆	◆	▲	◆	●	◆	●	▲	◆	◆	▲	▲	◆
Dabigatran	◆	◆	◆	◆	■	■	◆	◆	◆	■	■	◆	◆	◆
Dalteparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dipyridamole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Edoxaban	◆	◆	◆	◆	■	■	◆	◆	◆	■	■	◆	◆	◆
Enoxaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fondaparinux	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Heparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenprocoumon	▲	◆	◆	▲	■	■	■	●	▲	■	◆	▲	▲	◆
Prasugrel	▲	◆	◆	▲	◆	◆	◆	◆	▲	◆	◆	▲	▲	◆
Rivaroxaban	▲	◆	◆	▲	■	■	◆	■	▲	■	◆	▲	▲	◆
Streptokinase	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ticagrelor	▲	◆	◆	▲	◆	■	◆	■	▲	◆	▲	▲	▲	◆
Ticlopidine	■	■	◆	■	◆	●	◆	■	■	◆	■	■	■	◆
Tinzaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vorapaxar	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Warfarin	▲	◆	◆	▲	■	■	■	●	▲	■	◆	▲	▲	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 4 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Anticonvulsants														
Brivaracetam	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Carbamazepine	▲	◆	◆	▲	■	■	■	●	▲	■	■	▲	▲	◆
Cenobamate	◆	▲	◆	◆	■	▲	■	●	◆	■	■	◆	◆	◆
Clonazepam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Eslicarbazepine	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Ethosuximide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Gabapentin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Lamotrigine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Oxcarbazepine	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Perampanel	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Phenobarbital (Phenobarbitone)	▲	◆	◆	▲	■	■	■	●	▲	■	■	▲	▲	◆
Phenytoin	▲	◆	◆	▲	■	■	■	●	▲	■	■	▲	▲	◆
Pregabalin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Primidone	▲	◆	◆	▲	■	■	■	●	▲	■	■	▲	▲	◆
Retigabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rufinamide	◆	◆	◆	◆	■	◆	■	◆	◆	■	■	◆	◆	◆
Sodium valproate	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Tiagabine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Valproate semisodium (Divalproex)	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Valproic acid	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Vigabatrin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antidepressants														
Agomelatine	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Amitriptyline	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Bupropion	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Citalopram	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Clomipramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Desipramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Desvenlafaxine	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Doxepin	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Duloxetine	◆	◆	◆	◆	◆	●	◆	▲	◆	◆	◆	◆	◆	◆
Escitalopram	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Fluoxetine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Imipramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Lithium	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Maprotiline	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Mianserin	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Milnacipran	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Mirtazapine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Nefazodone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Nortriptyline	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Opipramol	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Paroxetine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Phenelzine	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Reboxetine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Sertraline	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Tranlycypromine	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Trazodone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Trimipramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Venlafaxine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Vilazodone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Vortioxetine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 5 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Anti-diabetics														
Acarbose	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Alogliptin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Canagliflozin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Dapagliflozin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Dulaglutide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Empagliflozin	◆	◆	◆	◆	■	■	■	◆	◆	■	■	◆	◆	◆
Exenatide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Glibenclamide (Glyburide)	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Gliclazide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Glimepiride	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Glipizide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Insulin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Linagliptin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Liraglutide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Metformin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Nateglinide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Pioglitazone	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Repaglinide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Rosiglitazone	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Saxagliptin	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Semaglutide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Sitagliptin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Tirzepatide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Tolbutamide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Vildagliptin	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Antifungals														
Amphotericin B	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Anidulafungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Caspofungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clotrimazole (pessary, troche)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Clotrimazole (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluconazole	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	■	◆	◆	◆
Flucytosine	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Griseofulvin	◆	◆	◆	◆	■	■	■	■	◆	■	■	◆	◆	◆
Isavuconazole	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	■	◆	◆	◆
Itraconazole	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Ketoconazole	◆	◆	▲	◆	◆	■	◆	◆	◆	◆	■	◆	◆	◆
Micafungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Miconazole	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Nystatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Posaconazole	◆	◆	▲	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Terbinafine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Voriconazole	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Antihemorrhagics														
Avatrombopag	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Eltrombopag	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Fostatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Tranexamic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antihistamines														
Azelastine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cetirizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorphenamine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Desloratadine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diphenhydramine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Doxylamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fexofenadine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levocetirizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loratadine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Meclizine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Promethazine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

◆	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 6 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Antimalarials														
Amodiaquine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Artemether	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Artesunate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atovaquone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chloroquine	■	■	◆	■	■	■	■	■	■	■	■	■	■	◆
Halofantrine	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	▲	▲	◆
Hydroxychloroquine	■	■	◆	■	■	■	■	■	■	■	■	■	■	◆
Lumefantrine	◆	◆	◆	◆	◆	●	◆	■	◆	◆	◆	◆	◆	◆
Mefloquine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Piperaquine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Primaquine	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Proguanil	◆	◆	◆	◆	◆	▲	◆	■	◆	◆	◆	◆	◆	◆
Pyrimethamine	■	■	◆	■	◆	▲	◆	◆	■	◆	■	■	■	◆
Quinine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Sulfadoxine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antimigraine Agents														
Almotriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Dihydroergotamine	◆	◆	◆	◆	◆	●	◆	●	◆	◆	■	◆	◆	◆
Eletriptan	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Eptinezumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erenumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ergotamine	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Fremanuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Frovatriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Galcanezumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naratriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Pizotifen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rimegepant	◆	◆	◆	◆	◆	■	◆	■	◆	◆	●	◆	◆	◆
Rizatriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Sumatriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Ubrogepant	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Zolmitriptan	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	■	◆	◆	◆
Antipsychotics/Neuroleptics														
Amisulpride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aripiprazole	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Asenapine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Brexipiprazole	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Cariprazine	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Chlorpromazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Clozapine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Flupentixol (Flupenthixol)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Fluphenazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Haloperidol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Iloperidone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Levomopromazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Lumateperone	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Lurasidone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Olanzapine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Paliperidone	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Perazine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Pericazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Perphenazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Pimavanserin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Pimozide	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Pipotiazine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Quetiapine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Risperidone	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Sulpiride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thioridazine	◆	◆	◆	◆	■	●	■	●	◆	■	■	◆	◆	◆
Tiapride	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Ziprasidone	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Zotepine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Zuclopenthixol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 7 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Antivirals														
Aciclovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Adefovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baloxavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brincidofovir	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bulevirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cidofovir	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Entecavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Famciclovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Foscarnet	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Ganciclovir	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Letermovir	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Maribavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oseltamivir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ribavirin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Rimantadine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tecovirimat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telbivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir alafenamide (HBV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valaciclovir (Valacyclovir)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valganciclovir	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Zanamivir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anxiolytics/Hypnotics/Sedatives														
Alprazolam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Bromazepam	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Buspirone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Chlordiazepoxide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Clobazam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Clorazepate	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Diazepam	◆	◆	◆	◆	◆	●	◆	■	◆	◆	◆	◆	◆	◆
Estazolam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Eszopiclone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Flunitrazepam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Flurazepam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Hydroxyzine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Lorazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lormetazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Midazolam (oral)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Midazolam (parenteral)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Oxazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Suvorexant	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Temazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Triazolam	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Zaleplon	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Zolpidem	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Zopiclone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Benign Prostatic Hyperplasia Therapies														
Alfuzosin	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Finasteride (5 mg)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Silodosin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Tadalafil (BPH)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 8 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Beta Blockers														
Atenolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bisoprolol	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Carvedilol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Metoprolol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nebivolol	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Oxprenolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propranolol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Pindolol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Sotalol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Timolol	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Bisphosphonates														
Alendronic acid (Alendronate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ibandronic acid (Ibandronate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Risedronic acid (Risedronate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zoledronic acid (Zoledronate)	◆	◆	◆	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆
Bronchodilators														
Acidinium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aminophylline	▲	◆	◆	▲	◆	■	◆	◆	▲	◆	◆	▲	▲	◆
Formoterol	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Glycopyrronium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indacaterol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ipratropium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Montelukast	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Olodaterol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Roflumilast	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Salbutamol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Salmeterol	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Terbutaline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Theophylline	▲	◆	◆	▲	◆	■	◆	◆	▲	◆	◆	▲	▲	◆
Tiotropium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Umeclidinium bromide	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Vilanterol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium Channel Blockers														
Amlodipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Diltiazem	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Felodipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nicardipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Nifedipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nisoldipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nitrendipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Verapamil	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Cancer Therapies														
Abemaciclib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Abiraterone	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Acalabrutinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Afatinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aldesleukin	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Alectinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alpelisib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Amivantamab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anastrozole	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Apalutamide	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Asciminib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Atezolizumab	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Avapritinib	■	■	◆	■	▲	●	▲	●	■	▲	■	■	■	◆
Axitinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 9 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Cancer Therapies (continued)														
Bendamustine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Bevacizumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Bexarotene	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Bicalutamide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Binimetinib	◆	▲	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Blinatumomab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Bortezomib	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Bosutinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Brentuximab vedotin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Brigatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Cabazitaxel	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Cabozantinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Capecitabine	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Capmatinib	◆	▲	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆
Carboplatin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Carfilzomib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Cemiplimab	◆	◆	◆	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆
Ceritinib	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Cetuximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorambucil	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Cobimetinib	◆	◆	◆	◆	◆	■	◆	■	■	◆	■	◆	◆	◆
Crizotinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Cyclophosphamide	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Dabrafenib	■	■	◆	■	■	■	■	●	■	■	■	■	■	◆
Dacarbazine	■	■	◆	■	◆	●	◆	■	■	◆	■	■	■	◆
Dacomitinib	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Dactinomycin	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Daratumumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Darolutamide	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dasatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Docetaxel	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Doxorubicin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Durvalumab	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Duvelisib	■	■	▲	■	◆	◆	◆	■	■	◆	■	■	■	◆
Elotuzumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Enasidenib	◆	▲	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Encorafenib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Enfortumab vedotin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Entrectinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Enzalutamide	◆	◆	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Epirubicin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Erdafitinib	◆	■	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Erlotinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Etoposide	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Exemestane	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fedratinib	■	●	▲	■	◆	▲	◆	■	■	◆	●	■	■	◆
Fluorouracil (5-FU)	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Flutamide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Fulvestrant	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gefitinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Gemcitabine	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Gilteritinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Glasdegib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Hydroxycarbamide (Hydroxyurea)	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 10 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Cancer Therapies (continued)														
Ibrutinib	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Idelalisib	■	■	▲	■	◆	■	◆	■	■	◆	■	■	■	◆
Imatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Infigratinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Inotuzumab ozogamicin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Ipilimumab	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Irinotecan	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Isotretinoin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Ivosidenib	◆	◆	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Ixazomib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Lapatinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Larotrectinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Lenalidomide	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Lenvatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Letrozole	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Lomustine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Lorlatinib	■	■	◆	■	■	■	■	●	◆	■	■	■	■	◆
Mercaptopurine	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Methotrexate	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Midostaurin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Mitotane	■	■	◆	■	■	◆	■	●	■	■	■	■	■	◆
Mobocertinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Necitumumab	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Neratinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Nilotinib	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Niraparib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Nivolumab	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Obinutuzumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Ofatumumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Olaparib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Olaratumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Osimertinib	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Oxaliplatin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Paclitaxel	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Palbociclib	■	■	◆	■	◆	▲	◆	▲	■	◆	■	■	■	◆
Panitumumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Panobinostat	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Pazopanib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Pembrolizumab	■	■	◆	■	■	◆	■	■	■	■	■	■	■	◆
Pemetrexed	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Pemigatinib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Pertuzumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Pexidartinib	■	■	◆	■	■	●	■	●	■	■	■	■	■	◆
Polatuzumab vedotin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Pomalidomide	■	■	◆	■	◆	■	◆	◆	■	◆	■	■	■	◆
Ponatinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Pralsetinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Regorafenib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Relugolix	◆	◆	◆	◆	◆	▲	◆	■	◆	◆	◆	◆	◆	◆
Ribociclib	■	■	▲	■	◆	■	◆	■	■	◆	■	■	■	◆
Ripretinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Rituximab	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Rucaparib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 11 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Cancer Therapies (continued)														
Selinexor	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Selpercatinib	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Sonidegib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Sorafenib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Sotorasib	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Sunitinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Talazoparib	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Tamoxifen	◆	◆	◆	◆	■	■	■	■	■	■	■	◆	◆	◆
Tegafur/ Gimeracil/ Oteracil	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Temsirolimus	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Tepotinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Thalidomide	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Tisotumab vedotin	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Tivozanib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Topotecan	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Toremifene	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Trametinib	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trastuzumab	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Trastuzumab emtansine	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Trifluridine/Tipiracil	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Umbralisib	■	■	◆	■	■	●	■	●	■	■	■	■	■	◆
Vandetanib	■	■	◆	■	◆	●	◆	●	■	◆	■	■	■	◆
Vemurafenib	■	■	◆	■	■	■	■	●	■	■	■	■	■	◆
Venetoclax	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Vinblastine	■	■	◆	■	▲	■	▲	■	■	▲	■	■	■	◆
Vincristine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Vinorelbine	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Zanubrutinib	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Contraceptives/HRT														
Conjugated estrogens (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desogestrel (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desogestrel (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Drospirenone (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Drospirenone (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dydrogesterone (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Estradiol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ethinylestradiol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etonogestrel (implant)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etonogestrel (vaginal ring)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gestodene (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (emergency contraception)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (implant)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (IUD)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (depot injection)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norelgestromin (patch)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (IM depot)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestimate (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestrel (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestrel (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Progesterone (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ulipristal	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 12 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Cough and Cold Preparations														
Benzonatate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbocisteine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dextromethorphan	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Guaifenesin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Covid-19 Antiviral Therapies														
Bamlanivimab/Etesevimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bebtelovimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Casirivimab/Imdevimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ensitrelvir	◆	◆	▲	◆	▲	◆	▲	■	◆	▲	■	◆	◆	◆
Favipiravir	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Molnupiravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Niclosamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nirmatrelvir + ritonavir (5 day)	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Nirmatrelvir + ritonavir (≥ 10 days)	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Nitazoxanide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Remdesivir	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆
Sotrovimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tixagevimab/Cilgavimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Covid-19 Host-directed Therapies														
Anakinra	■	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Baricitinib	●	■	◆	●	◆	▲	◆	■	●	◆	●	●	●	◆
Budesonide (inhaled)	◆	◆	■	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Canakinumab	●	●	◆	■	◆	◆	◆	■	●	◆	●	●	●	◆
Covid 19 convalescent plasma	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Covid-19 vaccines	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆
Dexamethasone (low dose; ≤16 mg)	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvoxamine	◆	◆	▲	◆	◆	■	◆	▲	◆	◆	■	◆	◆	◆
Hydrocortisone (oral or IV)	◆	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆	◆	◆
Imatinib (14 days)	■	■	◆	■	◆	▲	◆	■	■	◆	■	■	■	◆
Infliximab	●	●	◆	●	◆	◆	◆	■	■	◆	●	●	●	◆
Methylprednisolone (oral or IV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆
Ruxolitinib	●	●	◆	●	◆	■	◆	■	●	◆	■	●	●	◆
Sarilumab	●	●	◆	●	◆	◆	◆	■	●	◆	●	■	●	◆
Tocilizumab	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	■	◆
Vilobelimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Cystic Fibrosis Agents														
Ivacaftor	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Ivacaftor/lumacaftor	◆	▲	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Ivacaftor/tezacaftor	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Ivacaftor/tezacaftor/elexacaftor	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Dementia Therapies														
Donepezil	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Galantamine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rivastigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erectile Dysfunction Agents														
Avanafil	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Sildenafil (erectile dysfunction)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Tadalafil (erectile dysfunction)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Vardenafil	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 13 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Gastrointestinal Agents														
Alosetron	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Bisacodyl	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Bismuth subsalicylate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cimetidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Cisapride	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Dexlansoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dicycloverine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Docusate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Esomeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Famotidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine butylbromide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Lansoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Linaclotide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loperamide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Macrogol (Polyethylene Glycol 3350)	◆	▲	◆	◆	▲	▲	▲	▲	◆	▲	▲	◆	◆	◆
Magnesium salts (oral)	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Mebeverine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mesalazine (mesalamine)	■	■	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxegol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	▲	◆	◆	◆
Nizatidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Octreotide	◆	◆	◆	◆	◆	■	▲	■	◆	▲	▲	◆	◆	◆
Omeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pantoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prucalopride	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Psyllium husk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranitidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Senna	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Sucralfate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gastrointestinal Agents (anti-emetics)														
Aprepitant	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Cyclizine	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Dolasetron	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Domperidone	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Dronabinol	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Granisetron	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Hyoscine (Scopolamine)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Hyoscine hydrobromide	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Metoclopramide	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Ondansetron	◆	■	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Prochlorperazine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 14 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
HCV DAAs														
Elbasvir/Grazoprevir	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	▲	◆	◆	◆
Glecaprevir/Pibrentasvir	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	▲	◆	◆	◆
Ledipasvir/Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Ombitasvir/Paritaprevir/r	◆	◆	▲	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Ombitasvir/Paritaprevir/r + Dasabuvir	◆	◆	▲	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sofosbuvir/Velpatasvir	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆
Sofosbuvir/Velpatasvir/Voxilaprevir	◆	◆	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆
HIV Antiretroviral Therapies														
Abacavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Albuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atazanavir alone	◆	◆	▲	◆	◆	◆	◆	■	◆	◆	■	◆	◆	◆
Atazanavir + ritonavir	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Atazanavir/cobicistat	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Bictegravir/Emtricitabine/TAF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (long acting)	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆	◆	◆	◆
Darunavir + ritonavir	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Darunavir/cobicistat	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Darunavir/Cobi/Emtricitabine/TAF	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/Rilpivirine	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆	◆	◆	◆
Dolutegravir/Abacavir/Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine/Lamivudine/Tenofovir-DF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Efavirenz	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Elvitegravir/Cobi/Emtricitabine/TAF	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Elvitegravir/Cobi/Emtricitabine/TDF	◆	◆	▲	◆	◆	▲	◆	■	◆	◆	■	◆	◆	◆
Emtricitabine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine/Tenofovir alafenamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine/Tenofovir-DF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etravirine	◆	◆	◆	◆	■	▲	■	●	◆	■	■	◆	◆	◆
Fostemsavir	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Ibalizumab-uiyk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lenacapavir	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	■	◆	◆	◆
Lopinavir/ritonavir	◆	◆	▲	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Maraviroc	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Nevirapine	◆	◆	◆	◆	■	▲	■	●	◆	■	■	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilpivirine	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆	◆	◆	◆
Rilpivirine/Emtricitabine/TAF	◆	◆	◆	◆	■	■	◆	■	◆	◆	◆	◆	◆	◆
Rilpivirine/Emtricitabine/TDF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zidovudine	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 15 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Hypertension / Heart Failure Agents														
Aliskiren	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Ambrisentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Amiloride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azilsartan	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Benazepril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bendroflumethiazide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Bosentan	◆	◆	◆	◆	■	●	■	●	◆	■	■	◆	◆	◆
Bumetanide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Candesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Captopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorthalidone (Chlorthalidone)	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Cilazapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dopamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doxazosin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Enalapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eplerenone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Epoprostenol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eprosartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Finerenone	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Fosinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Furosemide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Glycerol trinitrate (Nitroglycerin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydralazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆	◆	■	■	■	◆	◆	■	◆	◆	◆	◆
Iloprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indapamide	◆	◆	◆	◆	■	■	■	▲	◆	■	◆	◆	◆	◆
Irbesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isosorbide dinitrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ivabradine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Labetalol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lacidipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Lercanidipine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Lisinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Losartan	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Macitentan	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Methyldopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metolazone	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆
Midodrine	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆
Minoxidil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moxonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Olmesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Perindopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prazosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Quinapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ramipril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranolazine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	▲	◆	◆	◆
Riociguat	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	■	◆	◆	◆
Sacubitril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Selexipag	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sildenafil (PAH)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Sodium nitroprusside	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Spironolactone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tadalafil (PAH)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Telmisartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Terazosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Torsemide	◆	◆	◆	◆	■	■	■	■	◆	■	◆	◆	◆	◆
Trandolapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Treprostinil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Triamterene	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Valsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Xipamide	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 16 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Illicit/Recreational														
Alcohol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amphetamine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Cannabis (Marijuana)	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Carfentanil	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Cocaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ecstasy (MDMA)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
GHB (Gamma-hydroxybutyrate)	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Heroin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
LSD (Lysergic acid diethylamide)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methamphetamine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Poppers (Amyl nitrate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Immunosuppressants														
Abatacept	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Abrocitinib	●	●	◆	●	◆	■	◆	■	●	◆	●	●	●	◆
Adalimumab	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Anti-thymocyte globulin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Apremilast	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azathioprine	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Basiliximab	●	●	◆	●	◆	◆	◆	◆	●	◆	●	●	●	◆
Belatacept	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Belimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Certolizumab pegol	●	●	◆	●	◆	◆	◆	■	●	◆	●	●	●	◆
Ciclosporin	▲	■	◆	▲	■	■	◆	■	▲	◆	■	▲	▲	◆
Dimethyl fumarate	◆	■	◆	■	◆	◆	◆	◆	■	◆	◆	◆	◆	◆
Etanercept	●	●	◆	●	◆	◆	◆	◆	●	◆	●	●	●	◆
Everolimus	◆	◆	◆	◆	▲	■	◆	■	◆	◆	◆	◆	◆	◆
Filgotinib	●	●	◆	●	◆	◆	◆	◆	●	◆	●	●	●	◆
Golimumab	●	■	◆	●	◆	◆	◆	■	●	◆	■	●	●	◆
Ixekizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Leflunomide	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Methotrexate	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Mycophenolate	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆
Pirfenidone	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Risankizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Secukinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sirolimus	▲	◆	◆	▲	■	■	◆	■	▲	◆	■	▲	▲	◆
Tacrolimus	▲	■	◆	▲	■	■	◆	■	▲	◆	■	▲	▲	◆
Tofacitinib	●	●	◆	●	◆	■	◆	■	●	◆	●	●	●	◆
Upadacitinib	●	●	◆	●	◆	■	◆	■	●	◆	●	●	●	◆
Ustekinumab	■	■	◆	■	◆	◆	◆	◆	■	◆	■	■	■	◆
Vedolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Voclosporin	◆	■	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 17 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Inotropes & Vasopressors														
Adrenaline (Epinephrine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dobutamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Noradrenaline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vasopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lipid Lowering Agents														
Alirocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atorvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bempedoic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bezafibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clofibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colesevelam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colestyramine (Cholestyramine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Evolocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fenofibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fish oils	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gemfibrozil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Icosapent ethyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Inclisiran	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lomitapide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lovastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pitavastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Omega-3 fatty acids	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pravastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rosuvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Simvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Multiple Sclerosis Agents														
Alemtuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cladribine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dantrolene sodium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dimethyl fumarate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fampridine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fingolimod	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glatiramer acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Natalizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ozanimod	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Peginterferon beta-1a	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Siponimod	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Teriflunomide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ophthalmological Agents														
Brimonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brolucizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Latanoprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranibizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Travoprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

◆	These drugs should not be coadministered
◆	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
◆	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 18 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Other														
Acetazolamide	■	■	◆	■	◆	■	◆	■	■	◆	■	■	■	◆
Acetylcysteine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acitretin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Allopurinol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betahistine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cannabidiol	◆	◆	◆	◆	◆	■	◆	■	◆	◆	▲	◆	◆	◆
Carbimazole	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Cinacalcet	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Clomifene	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Colchicine	◆	◆	◆	◆	▲	■	◆	■	◆	◆	■	◆	◆	◆
Crizanlizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cytisine (Cytisinicline)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Deferasirox	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Denosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Disulfiram	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Drotaverine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ergometrine (Ergonovine)	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Febuxostat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fezolinetant	◆	◆	◆	◆	◆	●	◆	▲	◆	◆	◆	◆	◆	◆
Filgrastim	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Finasteride (1mg)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flibanserin	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Glucosamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Goserelin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Interferon beta	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Isosorbide mononitrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ivermectin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Leuporelin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Levothyroxine	◆	◆	◆	◆	▲	◆	▲	■	◆	▲	◆	◆	◆	◆
Liothyronine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Magnesium sulfate (IV)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Mepolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methimazole	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Methylergometrine	◆	◆	◆	◆	◆	●	◆	●	◆	◆	◆	◆	◆	◆
Misoprostol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Modafinil	◆	◆	◆	◆	■	◆	■	◆	◆	■	■	◆	◆	◆
Naftidrofuryl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicotine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nintedanib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Omalizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orlistat	◆	▲	◆	◆	▲	▲	▲	▲	◆	▲	▲	◆	◆	◆
Ospemifene	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Pancreatic enzymes (Creon)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phentermine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Probenecid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propylthiouracil	■	■	◆	■	◆	◆	◆	■	■	◆	■	■	■	◆
Pyridostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 19 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Other (continued)														
Raloxifene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sevelamer	◆	▲	◆	◆	▲	▲	▲	▲	◆	▲	▲	◆	◆	◆
Sulfasalazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■	◆	◆	◆
Tolvaptan	◆	◆	◆	◆	◆	■	◆	■	◆	◆	■	◆	◆	◆
Triclabendazole	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Triptorelin	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Ursodeoxycholic acid (Ursodiol)	◆	◆	◆	◆	■	◆	■	●	◆	■	■	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Overactive Bladder Agents														
Darifenacin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Fesoterodine	◆	◆	◆	◆	◆	■	◆	▲	◆	◆	◆	◆	◆	◆
Mirabegron	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Oxybutynin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Solifenacin	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
Trospium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Parkinsonism Agents														
Amantadine	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆	◆
Apomorphine	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆
Benserazide/levodopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benzatropine (BENZTROPINE)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabergoline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Carbidopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbidopa/levodopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levodopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆
Piribedil	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Pramipexole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Procyclidine	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Rasagiline	◆	◆	◆	◆	◆	●	◆	◆	◆	◆	◆	◆	◆	◆
Ropinirole	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Rotigotine	◆	◆	◆	◆	◆	■	◆	◆	◆	◆	◆	◆	◆	◆
Steroids														
Beclometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betamethasone	◆	◆	◆	◆	■	▲	■	▲	◆	◆	■	◆	◆	◆
Budesonide (oral/rectal)	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Ciclesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasol	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Dexamethasone (>16 mg)	◆	◆	◆	◆	◆	▲	■	■	◆	■	■	◆	◆	◆
Difluprednate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fludrocortisone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Flunisolide	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Fluocinolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Megestrol acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylprednisolone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mometasone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Nandrolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxandrolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednisolone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Prednisone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Stanozolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Testosterone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆
Triamcinolone	◆	◆	◆	◆	◆	▲	◆	▲	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 18 December 2023

Page 20 of 20

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	ANR	BAR	BUD	CAN	DXM	FLV	HC	IMA	IFX	MP	RUX	SAR	TCZ	VIL
Vitamins/Supplements/Herbals														
African potato	◆	▲	◆	◆	◆	◆	◆	▲	◆	◆	▲	◆	◆	◆
Ayahuasca	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium supplements	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cat's claw (Uncaria tomentosa)	◆	◆	◆	◆	◆	◆	◆	▲	◆	◆	▲	◆	◆	◆
Coenzyme Q10 (Ubidecarenone)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ferrous fumarate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ferrous sulfate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glucosamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iron supplements	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Milk thistle (Silymarin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Multivitamins	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicotinamide (Niacinamide)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Red yeast rice	◆	◆	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆
St John's wort	◆	◆	◆	◆	■	■	■	●	◆	■	■	◆	◆	◆
Turmeric (Curcumin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin A (Retinol)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B1 (Thiamine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B12 (Cyanocobalamin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B2 (Riboflavin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B3 (Niacin, nicotinic acid)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B6 (Pyridoxine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B7 (Biotin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin C (Ascorbic Acid)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin D2 (Ergocalciferol)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin D3 (Calecalciferol)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin E (Tocopherol)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin K (Phytomenadione)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zinc	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ANR	Anakinra	FLV	Fluvoxamine	RUX	Ruxolitinib
BAR	Baricitinib	HC	Hydrocortisone	SAR	Sarilumab
BUD	Budesonide	IMA	Imatinib (14 days)	TCZ	Tocilizumab
CAN	Canakinumab	IFX	Infliximab	VIL	Vilobelimab
DXM	Dexamethasone	MP	Methylprednisolone		

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, LIVERPOOL, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.